Indian vaccine maker Bharat Biotech plans to upgrade at two plants to boost production of its COVID-19 vaccine Covaxin to nearly 700 million doses a year. Covaxin has 81% efficacy in its Phase 3 trial. #COVID19
Bharat says it’s looking to forge manufacturing upgrades with its partners in other countries, too. The company has teamed up with gene therapy specialist Ocugen stateside, which is on deck for clinical development, regulatory filing and commercialization in the U.S. Under the deal, the companies will split potential Covaxin profits in the U.S., with Ocugen in line for 45%.